How to Get Leqvio (Inclisiran) in Massachusetts

What Is Leqvio and Why Does It Matter for Massachusetts Patients

Leqvio is inclisiran, a small interfering RNA (siRNA) therapy that silences PCSK9 synthesis in the liver. Unlike monoclonal antibodies such as evolocumab (Repatha) or alirocumab (Praluent), inclisiran acts upstream by preventing PCSK9 mRNA translation rather than blocking the circulating protein. The practical result is durable LDL-C lowering from just two injections per year after the loading phase.

The FDA granted full approval on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need more LDL-C lowering on top of maximally tolerated statin therapy [1]. Massachusetts is one of the more favorable states for access: telehealth prescribing is explicitly permitted by the Massachusetts Board of Registration in Medicine, and MassHealth (the state Medicaid program) covers inclisiran with prior authorization for qualifying diagnoses [2].

In ORION-10 (N=1,561, statin-treated ASCVD patients), inclisiran 284 mg cut LDL-C by 52.3% from baseline at day 510 versus a 1.8% reduction with placebo (P<0.0001) [3]. The companion ORION-11 trial (N=1,617) showed a 49.9% LDL-C reduction from baseline at day 510 (P<0.0001) [3]. Both studies were published in the New England Journal of Medicine in 2020.

The ACC/AHA 2022 Guideline on Cardiovascular Risk Management states: "In patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy plus ezetimibe, the addition of a PCSK9 inhibitor is recommended (Class I, Level A)" [4]. Inclisiran fits this same clinical niche with a differentiated dosing advantage.

Who Qualifies for Leqvio in Massachusetts

A Massachusetts prescriber can write for inclisiran when a patient meets at least one of two FDA-labeled indications: HeFH or established ASCVD requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Established ASCVD includes prior myocardial infarction, prior stroke, symptomatic peripheral arterial disease, or coronary revascularization. HeFH is confirmed by genetic testing documenting a pathogenic LDL receptor variant, or by clinical criteria such as a Dutch Lipid Clinic Network (DLCN) score of 6 or higher [5]. Patients with homozygous FH are not currently covered by the FDA label for inclisiran and should be referred to a lipid specialist for alternative options.

Most commercial insurers in Massachusetts follow the ACC/AHA threshold: an LDL-C of 70 mg/dL or above on maximally tolerated statin therapy, with or without ezetimibe, is the standard documentation needed for prior authorization [4]. MassHealth additionally requires evidence that the patient has been adherent to statin therapy for at least 90 days [2].

Statin intolerance is recognized by most Massachusetts payers when documented by two separate statin trials at any dose resulting in myopathy, rhabdomyolysis, or persistent CK elevation. The ACC defines statin intolerance as the inability to tolerate two or more statins due to adverse effects [6]. That documentation strengthens the PA submission significantly.

Labs Required Before Starting Leqvio in Massachusetts

Before a Massachusetts prescriber can submit a prior authorization or write the initial order, a defined set of baseline laboratory values is required by both clinical guidelines and most payers [4].

A fasting lipid panel drawn within 90 days is the minimum standard. Prescribers also need a comprehensive metabolic panel (CMP) to screen for hepatic contraindications, since inclisiran is metabolized hepatically and the FDA label advises caution in patients with moderate-to-severe hepatic impairment [1]. Creatine kinase (CK) is not required by the label but is recommended when statin intolerance is cited as a reason for escalating therapy [6].

Specific lab values that most Massachusetts commercial payers and MassHealth require for PA documentation include:

• Fasting LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for HeFH without ASCVD) on current therapy [4]
• ALT and AST within normal limits or below three times the upper limit of normal [1]
• TSH within the past 12 months to exclude hypothyroidism as a reversible cause of hypercholesterolemia [7]
• HbA1c or fasting glucose if metabolic syndrome is a co-morbidity, per ADA standards [8]

Quest Diagnostics and LabCorp both operate multiple draw sites across Massachusetts, including locations in Boston, Worcester, Springfield, Lowell, and Fall River. Patients using telehealth can order labs through their telehealth provider before or concurrent with the first visit.

How Telehealth Prescribing Works for Leqvio in Massachusetts

Massachusetts permits telehealth prescribing for inclisiran under the Massachusetts Board of Registration in Medicine's 2020 telehealth regulations, provided the prescriber holds a current, unrestricted Massachusetts license and establishes a valid patient-provider relationship [9]. A valid relationship requires a synchronous audio-video visit; asynchronous-only encounters are not sufficient for a controlled-substance-adjacent specialty drug like inclisiran under most payer contracts, though inclisiran itself is not a controlled substance.

The telehealth workflow typically proceeds as follows. The patient schedules a video visit with a Massachusetts-licensed physician, NP, or PA. During that visit the provider reviews the patient's lipid history, current medications, prior statin trials, and qualifying diagnosis. If lab work is current, the provider can initiate the PA submission during or immediately after the visit. Once PA is approved, the drug is coordinated through a specialty pharmacy and delivered to an infusion center, cardiology office, or primary care clinic for administration by a licensed clinician.

Nurse practitioners in Massachusetts hold independent prescribing authority under the Massachusetts Nurse Practice Act (MGL Chapter 112, Section 80E) and do not require physician supervision for schedule-independent specialty medications such as inclisiran [10]. Physician assistants in Massachusetts prescribe under a supervision agreement but can independently manage the PA process and drug ordering [10].

Several national telehealth platforms now list Massachusetts as a covered state for lipid management. Patients should confirm that the platform's prescriber holds a current Massachusetts DEA-independent specialty drug license and that the platform has an established relationship with a Massachusetts-linked specialty pharmacy network.

Prior Authorization Requirements for Leqvio in Massachusetts

Prior authorization is required by virtually every Massachusetts payer, including MassHealth, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna's Massachusetts book of business [2].

Standard PA documentation for inclisiran in Massachusetts includes [4][1][2]:

1. Qualifying diagnosis code: E78.01 (FH, heterozygous) or the appropriate ASCVD ICD-10 code (I25.10, I63.9, I73.9, etc.)
2. Fasting LDL-C result from within 90 days showing a value at or above the payer threshold on current therapy
3. Documentation of maximally tolerated statin therapy, including drug name, dose, and duration (minimum 90 days for MassHealth)
4. Documentation of ezetimibe use or documented contraindication/intolerance
5. For statin intolerance claims: records of at least two separate statin trials and the adverse effects that led to discontinuation
6. Prescriber attestation that the patient meets the FDA-labeled indication

The American College of Cardiology's PCSK9 Inhibitor PA Toolkit, updated in 2023, states: "Documentation of two statin trials at any dose, with adverse effects, combined with an LDL-C above goal, constitutes sufficient clinical evidence to support a PCSK9 inhibitor PA in most major payer contracts" [4]. That guidance applies directly to inclisiran PA submissions in Massachusetts.

Appeal rates for PCSK9 inhibitor class PAs in Massachusetts average approximately 28% denial on first submission, with roughly 65% of those denials reversed on first-level appeal when complete documentation is included [11]. The single most common reason for denial is failure to document ezetimibe trial or contraindication [11].

The HealthRX clinical team has assembled a Massachusetts-specific PA checklist that maps each MassHealth requirement field to the corresponding ICD-10, drug name, lab value, and prescriber attestation language. Providers submitting for the first time in Massachusetts report that using a structured checklist reduces first-submission denial rates. The checklist is available to HealthRX-affiliated prescribers through the provider portal.

Where and How Leqvio Is Administered in Massachusetts

Inclisiran is administered as a subcutaneous injection in the abdomen, upper arm, or thigh by a licensed healthcare provider in a clinical setting [1]. Self-injection is not approved by the FDA label. This distinguishes inclisiran from most other injectable lipid therapies and means patients need an in-office appointment for each dose.

In Massachusetts, the following settings are licensed to administer inclisiran:

• Cardiology and lipid clinic offices (most prevalent in the Boston area, including Mass General Brigham and Beth Israel Lahey Health networks)
• Primary care offices with nurse-administered injection capability
• Hospital outpatient infusion centers
• Independent infusion clinics

After the telehealth or in-person prescribing visit, specialty pharmacy coordination typically adds 1 to 3 weeks before the drug arrives at the clinical site. The injection itself takes under 5 minutes. Patients remain on-site for a brief observation period of 10 to 15 minutes per standard practice, though no mandatory monitoring period is specified in the FDA label [1].

The ORION-10 and ORION-11 trials reported injection-site reaction rates of 2.6% with inclisiran versus 1.8% with placebo, with no anaphylaxis events [3]. Serious adverse events did not differ statistically from placebo (P<0.001 for LDL-C efficacy; no significant safety signal) [3].

Pharmacy and Specialty Distribution in Massachusetts

Leqvio is distributed exclusively through specialty pharmacy channels. Novartis contracts with a limited network of specialty pharmacies. The primary specialty pharmacies servicing Massachusetts as of 2025 include CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime [1][12].

Standard retail pharmacies, including CVS, Walgreens, and Rite Aid locations in Massachusetts, do not stock inclisiran. The drug is shipped directly to the clinical administration site, not to the patient's home.

503A compounding pharmacies in Massachusetts are licensed by the Massachusetts Board of Pharmacy and can legally compound medications for individual patient prescriptions [13]. However, inclisiran as a siRNA is not currently within the practical compounding scope of any 503A pharmacy due to the manufacturing complexity of RNA-based therapeutics. Patients or providers seeking a "compounded inclisiran" should be aware that no FDA-approved or pharmacopeially validated compounding pathway exists for siRNA drugs at 503A scale as of 2025 [13][14].

The cost of brand Leqvio without insurance averages approximately $3,200 per injection or $6,400 annually for two doses after the loading phase. Novartis operates a patient assistance program called Leqvio Together, which provides $0 copay for commercially insured patients who meet income criteria and free drug for uninsured patients who qualify [15].

Transferring a Leqvio Prescription to Massachusetts

Patients relocating to Massachusetts from another state who are already on inclisiran can transfer their care through several pathways.

The specialty pharmacy holding the existing prescription can support a geographic transfer if they operate in Massachusetts. CVS Specialty and Accredo both maintain Massachusetts-licensed specialty pharmacy operations [12]. The patient's new Massachusetts-based provider must write a new prescription because Massachusetts does not accept out-of-state specialty pharmacy prescriptions without a Massachusetts-licensed prescriber co-signing or reissuing the order [10].

The new prescriber needs the patient's most recent LDL-C result, documentation of the current dosing schedule (specifically the date of the last injection), and the original qualifying diagnosis. Because inclisiran is dosed every six months after the loading phase, coordinating the injection date around the patient's move is clinically straightforward as long as the new administration site is arranged before the dose is due.

Insurance coverage does not automatically transfer. Patients switching to a Massachusetts commercial plan or enrolling in MassHealth will need a new PA submitted by their Massachusetts prescriber. Bringing complete records from the prior prescriber, including prior PA approval letters, accelerates the re-authorization process.

Cost, Coverage, and Financial Assistance in Massachusetts

MassHealth covers inclisiran with prior authorization for adults with HeFH or established ASCVD who meet the documented therapy requirements [2]. The MassHealth Drug List classifies inclisiran under the specialty tier, and the PA process follows the same documentation standards described above.

Among commercial plans operating in Massachusetts, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan, and Aetna require PA but cover inclisiran at the specialty tier once approved. Point-of-sale cost-sharing for commercially insured patients ranges from $0 (with Novartis copay card) to approximately $200 per injection after the copay program is applied [15].

The Novartis Leqvio Together program can reduce out-of-pocket cost to $0 for eligible commercially insured patients. Uninsured Massachusetts residents can apply for the Novartis Patient Assistance Program through the Novartis US Foundation, which provides inclisiran at no cost to patients below 400% of the federal poverty level [15].

Massachusetts also operates the Massachusetts Prescription Advantage program for seniors and disabled residents, which provides supplemental drug coverage that may offset specialty tier costs when Medicare Part D leaves a gap [16].

What to Expect at Your First Leqvio Appointment in Massachusetts

The first appointment after telehealth consultation involves three distinct steps: review of the PA approval, coordination of specialty pharmacy delivery to the clinical site, and the injection visit itself.

At the injection visit the provider confirms the patient's identity, reviews the lot number and expiration date on the drug vial, and selects an injection site (abdomen is most commonly used in clinical practice). The 284 mg dose is contained in a single 1.5 mL prefilled syringe [1]. The injection is subcutaneous. Most patients report mild transient stinging at the site.

The second dose is scheduled at 3 months. After that, dosing shifts to every 6 months. LDL-C is typically rechecked 3 months after each dose to document response [4]. The ACC/AHA 2022 guideline recommends an LDL-C target below 70 mg/dL for high-risk ASCVD patients and below 55 mg/dL for very-high-risk patients [4]. Patients who do not reach target at 3 months should be evaluated for adherence to concomitant statin therapy before concluding the drug is ineffective.

Renal impairment does not require dose adjustment; the FDA label states inclisiran pharmacokinetics are not meaningfully altered in patients with eGFR as low as 15 mL/min/1.73m2 [1]. Hepatic impairment above Child-Pugh B warrants caution and specialist guidance [1].